

Conformational ensemble of the human TRPV3 ion channel

Lejla Zubcevic^{1,†}, Mark A. Herzik Jr.^{2,†}, Mengyu Wu^{2,3,†}, William F. Borschel¹, Marscha Hirschi¹, Albert Song^{2,3}, Gabriel C. Lander^{2,*}, Seok-Yong Lee^{1,*}

Affiliations:

¹ Department of Biochemistry, Duke University Medical Center, Durham, North Carolina, USA.

² Department of Integrative Structural and Computational Biology, Scripps Research, La Jolla, California, USA.

³ Skaggs Graduate School of Chemical and Biological Sciences, Scripps Research, La Jolla, California, USA.

[†] These authors contributed equally.

*Correspondence to:

S.-Y. Lee (seok-yong.lee@duke.edu) and G.C. Lander (glander@scripps.edu)

Summary

Transient receptor potential vanilloid channel 3 (TRPV3), a member of the thermosensitive TRP (thermoTRPV) channels, is activated by warm temperatures and serves as a key regulator of normal skin physiology through the release of pro-inflammatory messengers. Mutations in *trpv3* have been identified as the cause of the congenital skin disorder, Olmsted syndrome. Unlike other members of the thermoTRPV channel family, TRPV3 sensitizes upon repeated stimulation, yet a lack of structural information about the channel precludes a molecular-level understanding of TRPV3 sensitization and gating. Here, we present the cryo-electron microscopy structures of apo and sensitized human TRPV3, as well as several structures of TRPV3 in the presence of the common thermoTRPV agonist 2-aminoethoxydiphenyl borate (2-APB). Our results show α -to- π -helix transitions in the S6 during sensitization, and suggest a critical role for the S4-S5 linker π -helix during ligand gating.

Introduction

Transient Receptor Potential (TRP) channels are a superfamily of cation-selective ion channels that are involved in numerous physiological processes¹. The vanilloid TRP (TRPV) subfamily consists of six members (TRPV1-TRPV6), four of which (TRPV1-TRPV4) are involved in temperature sensing and therefore referred to as thermosensitive TRPV (thermoTRPV) channels. In addition to heat, thermoTRPV channels are also modulated by synthetic and natural ligands as well as lipids²⁻¹⁰. Although the thermoTRPV channels share >50% homology, each channel possesses a distinct functional and pharmacological profile that enables integration of a multitude of different stimuli into a finely tuned response^{1,11,12}.

In contrast to other thermoTRP channels, TRPV3 sensitizes, rather than desensitizes, upon repeated stimulation with either heat or agonists¹³⁻¹⁵. Notably, TRPV3 sensitization is inherent to the channel and independent of the modality of the stimulus. The channel undergoes hysteresis, which irreversibly lowers the energetic barrier for activation, resulting in a faster rate of activation and higher open probability¹⁵. TRPV3 is most abundantly expressed in epidermal and hair follicle keratinocytes where it plays a key role in maintenance of normal skin physiology^{13,16,17}. Activation of TRPV3 in keratinocytes has been shown to lead to release of pro-inflammatory messengers, and several ‘gain-of-function’ mutations in *trpv3* have been found to cause the human congenital skin disorder Olmsted syndrome, characterized by bilateral mutilating palmoplantar keratoderma, periorificial keratotic plaques, and hair loss with follicular papules¹⁸⁻²⁵. Therefore, TRPV3 plays essential roles in epidermal proliferation, differentiation, survival, hair growth, and the development of itch sensation²⁶. Several small-molecule inhibitors of TRPV3 have demonstrated analgesic properties in inflammatory and neuropathic pain models^{27,28}.

High-resolution structures of thermoTRPV channels captured in various states along the gating cycle have been critical to understanding the molecular underpinnings that govern both general and individual functional modalities of thermoTRPV channels²⁹⁻³³. However, as the structure of TRPV3 has yet to be determined, a large gap currently exists in our mechanistic understanding of thermoTRPV channel sensitization in activation and regulation. To fill this knowledge gap, we determined the cryo-EM structures of human TRPV3 in apo and sensitized states at ~3.4 Å and ~3.2 Å resolution, respectively. We additionally determined three conformationally distinct states of TRPV3 in the presence of the agonist 2-aminoethoxydiphenyl borate (2-APB), at resolutions ranging from ~3.5 – 4 Å, where we observe a departure from the canonical four-fold symmetry previously reported for most thermoTRPV structures (Fig. 1a, Fig. 2, Supplementary Figs. 1-3). Together, these structures illustrate the importance of π -helical segments in the transmembrane domain of TRPV3 in dictating the conformational landscape during sensitization and gating.

Results

Extensive screening of various TRPV3 homologs and mutants identified human TRPV3 containing the point mutation T96A as optimal for structural studies (see Methods). Characterization of both T96A and wild-type channels confirmed that the T96A mutation did not significantly alter the ligand-dependent gating profile of the TRPV3 channel (Fig. 1c-d, Supplementary Fig. 4). Whole-cell electrophysiological recordings show that TRPV3 T96A channels are functionally active and sensitize to repeated applications of the agonist 2-aminoethoxydiphenyl borate (2-APB; 30 μ M) with a sigmoidal time course of sensitization, similar to wild-type channels (Fig. 1c-d). There were no significant differences between sensitization parameters for both the time course and extent of sensitization for wild-type and

T96A channels, indicating the T96A mutation does not alter agonist-induced hysteresis of gating and subsequent sensitization of TRPV3 (Supplementary Fig. 4).

Architecture of human TRPV3

We determined the structure of full-length, human TRPV3_{T96A}, hereafter simply referred to as TRPV3, in the closed apo state to ~3.4 Å using cryo-electron microscopy (cryo-EM) (see Methods) (Fig. 1a and Table 1). The TRPV3 channel, like other thermoTRPV channels (TRPV1, TRPV2 and TRPV4³⁰⁻³³), is a four-fold symmetric homotetramer. Each monomer contains an amino- (N-) terminal cytosolic ankyrin repeat domain (ARD) and a domain-swapped transmembrane domain (TMD) comprising six transmembrane helices (S1-S6). The TMD and ARD are connected via the coupling domain (CD), which consists of the linker domain, pre-S1, and the carboxy- (C-) terminal domain (CTD). The TMD consists of a voltage sensor-like domain (VSLD) containing helices S1-S4, and a pore domain comprising helices S5, S6 and the pore helix. The VSLD and the pore domain are connected via an S4-S5 linker, which mediates the domain-swap configuration. In addition, the channel contains a TRP domain (Fig. 1b). The stabilizing T96A mutation, located N-terminal to the ARD in a region (residues 1-117), was not resolved in our 3D reconstructions (Supplementary Fig. 1).

Comparison of our closed, apo TRPV3 structure to the previously determined apo structures of the TRPV1³⁰ (PDB 3J5P), TRPV2³¹ (PDB 5AN8) and TRPV4³³ (PDB 6BBJ) channels reveals several new and notable features. First, the high quality of the TRPV3 EM density map has allowed us to build the most complete thermoTRPV CTD to date (residues 707-754), a region that was not well resolved in the cryo-EM structures of TRPV1, TRPV2 or TRPV4²⁹⁻³³. The most N-terminal region of the CTD, which extends from the TRP domain into the cytosol, forms a short α -helix similar to that observed in TRPV4³³, but in contrast to the loops observed in TRPV1 and TRPV2^{29,30,32} (Fig. 1b). The CTD extends into the cytosol,

forming a short two-stranded β -sheet before adding an additional strand to the β -sheet of the CD. In contrast to previously characterized TRPV channel structures, the C-terminal end of the CTD encircles the CD and loops across the peripheral side of the CD to interact with the ARD of the neighbouring protomer (Fig. 3a). This extended CTD establishes previously unobserved intra- and inter-subunit interactions that may serve a functional role (see “The CTD mediates inter-protomer contacts” section for further discussion). Second, the selectivity filter (SF, residues 636-640) of TRPV3 is lined with backbone carbonyls, whereas the SFs of TRPV1 and TRPV2 are occluded by hydrophobic amino acid side-chains, such as methionine. Similarly to the SF in TRPV4, the TRPV3 SF is sufficiently wide (~ 7 Å) to permeate a semi-hydrated calcium ion (Fig. 3b). Third, we previously predicted that the presence of π -helices in the strategically important S4-S5 linker and S6 in TRPV channels likely acts as transient flexible hinge points that facilitate channel gating³¹. Indeed, apo TRPV3 possesses a π -helix in the S4-S5 linker, whereas S6 is fully α -helical (Fig. 3c).

The sensitized state of the TRPV3 channel

In order to elucidate the molecular mechanism underlying TRPV3 sensitization, we determined the ~ 3.2 Å cryo-EM structure of TRPV3 that had been sensitized with the agonist 2-APB via a sensitization protocol developed in-house using electrophysiological results (see Methods, Supplementary Fig. 2). Comparison of this sensitized structure to the apo state did not reveal any substantive structural changes, with a 1.2 Å $\text{C}\alpha$ root mean square deviation (R.M.S.D.). However, closer inspection of the pore revealed that 2-APB sensitization resulted in the formation of a π -helix in S6 and a consequent change in register of the pore-forming residues (Fig. 4a). Specifically, while the α -helical S6 in apo TRPV3 imposes a narrow constriction at residue M677, the sensitized TRPV3 contains a π -helix that begins at residue F667 and changes the register of the S6 helix, resulting in a constriction at I674 (Fig. 4a-b).

In addition, the C-terminal half of the S6 helix in the sensitized structure is bent at a ~9° angle towards the inner pore when compared to the S6 in the apo structure (Fig. 4c). This bend is caused by the disruption of interactions between the S6 and the S4-S5 linker of the neighboring protomer, in the vicinity of the vanilloid binding site in TRPV1^{29,34-37}. In the apo structure, where the S6 helix is entirely α -helical, two pairs of interactions are present between S6 and the S4-S5 linker: one between residue N671 in S6 and the backbone carbonyl of Y575 located in the S4-S5 linker, and the other between the hydroxyl group of Y575 and the backbone amide of M672 within S6. Together, these interactions between S6 and the S4-S5 linker stabilize a straight, α -helical conformation of S6 (Fig. 5a). The register shift in S6 of the sensitized structure disrupts these interactions, releasing S6 and allowing it to bend away from the S4-S5 linker. In this structure, residue N671 faces the pore and appears to stabilize the π -helix by interacting with the backbone carbonyl of V666. (Fig. 5b).

Notably, N671 is the only polar residue in the S6 helix of TRPV3 (Fig. 5c) and we observe here that it adopts distinct positions depending on the functional state of the channel: either facing the S4-S5 linker in the apo state, or facing the pore in the sensitized state. This suggests that, in addition to introducing a flex point into S6, the α -to- π transition also decreases the hydrophobicity of the pore and provides a potential ion coordination site. The high sequence conservation of N671 in TRP channels (Fig. 5c) suggests that its functional and structural roles might also be conserved. These observations support our prior proposal that state-dependent α -to- π transitions in S6 occur in thermoTRPV channels³¹, and reflect the α -to- π transition described for TRPV6 channel opening³⁸. However, while the transition in TRPV6 was induced by a mutation, the transition in TRPV3 described here represents the first observation of a ligand-induced transition from a low-energy α - to a high-energy π -helix.

Structures of TRPV3 in the presence of 2-APB demonstrate a departure from four-fold symmetry

To elucidate the conformational changes governing transition of TRPV3 from the closed to the open state, we determined structures of the channel in the presence of the agonist 2-APB (TRPV3_{2-APB}, See Methods). A single cryo-EM dataset yielded three distinct conformations, TRPV3_{2-APB 1}, TRPV3_{2-APB 2}, and TRPV3_{2-APB 3}, (Fig. 2, Supplementary Fig. 3, Supplementary Fig. 5), all of which resolved to ~4 Å resolution or better. Strikingly, two out of the three TRPV3_{2-APB} structures exhibit two-fold (C2) symmetry (TRPV3_{2-APB 2}, and TRPV3_{2-APB 3}, Fig. 2), deviating from the canonical four-fold (C4) symmetry previously associated with thermoTRPV channels²⁹⁻³³. Notably, a thorough reanalysis of the apo TRPV3 datasets yielded no evidence of structural species containing symmetries lower than C4 (see Supplementary Fig 1). The reduced symmetry is conspicuous in the pores of the TRPV3_{2-APB 2} and TRPV3_{2-APB 3} structures, where movement in the C-terminal region of S6 in diagonally opposing protomers results in asymmetric gate arrangements within the channels (Fig. 6a-b). In TRPV3_{2-APB 2}, (Fig. 6a) the distance between the M677 residues in subunits A and C is ~5.7 Å, similar to the diameter of the closed gate of apo TRPV3 (~5.2 Å). However, in subunits B and D this distance is increased to ~9.1 Å which is similar to the ~9.3 Å diameter measured between gate residues in the structure of TRPV1 bound to double-knot toxin (DkTx) and resiniferatoxin (RTx)²⁹. However, TRPV3_{2-APB 2} is likely to be non-conductive, as the narrow opening of subunits A and C constricts the pore (Fig. 6b). It is thus possible that this arrangement of subunits represents an intermediate state. The two-fold symmetry is present not only in the pore of TRPV3_{2-APB}, but also across the entire channel (Fig. 2).

To better understand how these states deviate from the canonical C4-symmetric organization, we overlaid the sensitized TRPV3 structure with that of TRPV3_{2-APB 2}. Due to the domain-swapped configuration of the TMDs, each subunit is composed of the VSLD of one protomer

and the pore domain of the neighboring protomer. In this arrangement, the S4-S5 linker connects each subunit to its neighbor (Fig. 7a). The overlay of the sensitized TRPV3 structure with that of TRPV3_{2-APB 2} indicates that while TMDs of subunits A and C appear to be nearly identical between the two conformations, the TMDs of subunits B and D in TRPV3_{2-APB 2} undergo a ~3° rotation with respect to that of sensitized TRPV3 (Fig. 7a and Supplementary Fig. 6).

C2 symmetry is also present in the ARDs, where two of the ARDs are rotated with respect to the central axis of the pore and the remaining two assume the same conformation as in the sensitized TRPV3 (Supplementary Fig. 6). Surprisingly however, the deviating ARD is the one coupled to subunit B via the ARD-CTD interface, rather than the ARD directly connected to subunit B via the coupling domain (Supplementary Fig. 6). We therefore reason that this ARD is part of subunit B and that ARDs and TMDs are coupled through the ARD-CTD interface.

A rigid body superposition of the B subunits from the sensitized TRPV3 and TRPV3_{2-APB 2} structures results in good alignment (C_α R.M.S.D.= 0.9 Å), with only the S4-S5 linker deviating significantly. This suggests that the S4-S5 linker is the origin of the rotation observed in subunit B of TRPV3_{2-APB 2} (Fig. 7b). Different conformations of the S4-S5 linker were also observed when subunits A and B of TRPV3_{2-APB 2} were superposed (C_α R.M.S.D.= 0.9 Å), indicating that this region is the source of C2 symmetry in the TRPV3_{2-APB 2} structure (Fig. 7c).

Interestingly, an overlay of S5 helices of subunits A and B revealed that their S4-S5 linkers contain π -helices that originate at two different positions: at residue L584 in subunit A and at residue M579 in subunit B (Fig. 7d). Since the π -helices dictate the angle between subunits, it is likely that the differing positions of S4-S5 π -helices within the tetramer are responsible for

the two-fold symmetric arrangement of the channel. Because the break from C4 symmetry is only evident in structures obtained in the presence of 2-APB, we posit that the TRPV3 channel can assume reduced symmetry intermediates. Interestingly, a similar departure from C4 symmetry arising from a rearrangement of the S4-S5 linker was observed in the crystal structure of TRPV2 upon binding RTx³⁹. Notably, the gain-of-function mutations that cause Olmsted syndrome are located in the S4-S5 linker and its junctions with the S4b, S3, the TRP domain, and the lower part of S6, underscoring the importance of the S4-S5 linker in TRPV3 channel gating (Supplementary Fig. 7).

Although our reconstructions did not enable unambiguous identification of 2-APB, distinct non-polypeptide densities were observed in both the vanilloid binding pocket as well as in the cavity formed by the VSLD and the TRP domain (Supplementary Figure 8). The latter was recently identified as the binding site for 2-APB in TRPV6⁴⁰, for which it has an inhibitory, rather than activating effect on the channel. However, since both sites are often occupied by putative lipid molecules^{29,31,41-43}, it is difficult to determine whether the observed densities belong to the bound ligand or a lipid. Furthermore, the density in the VSLD cavity remains consistent in all of our TRPV3 reconstructions.

The CTD mediates inter-protomer contacts

Notably, TRPV3 contains an extended CTD that has not been resolved in the previously reported cryo-EM structures of TRPV1, TRPV2 or TRPV4²⁹⁻³³. The distal region of the CTD wraps around the β-sheet of the coupling domain at the interface between two neighbouring protomers, where it contacts the ARD finger 2 (Fig. 3a). Previous studies have identified numerous residues on the ARD finger 2 that are important for TRPV3 channel gating.⁴⁴. In addition, this region of the ARD has been implicated in binding calmodulin (CaM) and ATP, and biochemical and structural studies of isolated ARDs have further identified the conserved

residue K169 as being critical for ATP binding⁴⁵⁻⁴⁷. However, in our structures, we observe that K169 in the ARD of one protomer forms salt bridges with residues E751 and D752 located in the CTD of the adjacent protomer (Supplementary Fig. 9). Therefore, binding of CaM or ATP to the proposed ARD binding site involving K169 would not be possible for the conformations captured in this study, as the CTD and ATP binding sites on the ARDs appear to overlap (Supplementary Fig. 9).

Our structural analyses suggests an important role for the extended CTD in channel gating, specifically in mediating the mechanic coupling of the ARDs and TMs. Interestingly, sequence comparison with other thermoTRPV channels strongly suggests that the extended CTD is a conserved feature in thermoTRPV (Supplementary Fig. 9). In the context of previous studies, it is tempting to speculate that the CTD and CaM/ATP might compete for binding at finger 2 of the ARD and that this competition might be a part of a regulatory mechanism in TRPV3.

Discussion

We determined the structures of the human TRPV3 channel in multiple conformational states, providing a glimpse of putative gating intermediates. The apo structure of TRPV3, despite being closely related to other thermoTRPV channels, shows a number of unique features. Most notably, in contrast to the selectivity filters (SFs) of TRPV1 and TRPV2^{30,31}, which are occluded by side chains of hydrophobic residues, the SF of TRPV3 is lined with backbone carbonyl groups and is wide enough to permeate partially dehydrated cations. Interestingly, the SF remains mostly unchanged in all the conformational states captured, which suggests that the SF in TRPV3 does not act as a gate, in contrast to TRPV1 and TRPV2.

TRPV3 is unique among TRP channels in that it sensitizes upon repeated application of stimuli. Here we have shown that sensitization of the TRPV3 channel involves a change in the secondary structure of the pore-lining helix S6, which adopts a α -helix. The α -to- π transition in S6 has been predicted to play an important role in TRPV channel gating by introducing a hinge in the S6 analogous to glycine and proline hinges in K^+ channels^{17,48}. However, in contrast to the hinges in K^+ channels which are engineered into the amino acid sequence, the π -helix hinge was predicted to form depending on the functional state of the channel³¹. We propose that the transition from α - to π -helix is an essential component of TRPV3 hysteresis.

Unexpectedly, the presence of 2-APB in the sample induces a departure from C4 symmetry within the channel. The two-fold symmetric expansion of the gate was not observed in apo or sensitized TRPV3, and only manifested upon 2-APB addition, leading us to speculate that the two TRPV3_{2-APB} structures we observe represent intermediate states associated with gating function. Intriguingly, normal mode analysis of the backbone (C α) of the C4-symmetric channel, which was performed to estimate possible global protein conformations of TRPV3, resulted in trajectories that recapitulated the experimentally observed adoption of the C2-symmetric states (Supplementary Fig. 10). Additional evidence of C4 symmetry departure comes from a recent structure of the closely related TRPV2 channel fully bound to RTx, which also adopted a two-fold symmetric arrangement³⁹, suggesting that the ability to enter C2-symmetric states during the gating cycle is a shared feature of thermoTRPV channels. Furthermore, recent cryo-EM studies of the structural transitions of the Na^+ -activated K^+ channel Slo2.2 channel upon Na^+ titration did not reveal intermediate two-fold symmetric arrangements⁴⁹, indicating that TRPV channels may utilize a fundamentally different gating mechanism from architecturally-related K^+ channels.

Acknowledgments All cryo-EM data were collected at the Scripps Research (SR) electron microscopy facility. We thank A. Patapoutian at SR for his generosity in providing access to his mutant TRPV3 library. We thank J. Grandl for the guidance with mutant selection and analyses. We thank J.C. Ducom at SR High Performance Computing facility for computational support and B. Anderson for microscope support. We thank S. Thomas for initial TRPV3 biochemistry. This work was supported by the National Institutes of Health (R35NS097241 to S.-Y.L., DP2EB020402 and R21AR072910 to G.C.L.). G.C.L is supported as a Searle Scholar and a Pew Scholar in the Biomedical Sciences, supported by the Pew Charitable Trusts. M.A.H. is supported by a Helen Hay Whitney Foundation postdoctoral fellowship. Computational analyses of EM data were performed using shared instrumentation at SR funded by NIH S10OD021634.

Author Contributions L.Z. conducted biochemical experiments of TRPV3 and model building and refinement, W.F.B. carried out electrophysiological recordings, M.H. conducted sequencing of mouse TRPV3 clones and initial TRPV3 biochemistry, all under the guidance of S.-Y.L. S.Y.L. conceived the idea to isolate stabilizing mutations from the TRPV3 mutant library. A.S. performed the normal mode analysis under the guidance of M.A.H. M.A.H. and M.W. conducted all cryo-EM experiments under the guidance of G.C.L. L.Z. S.-Y.L., G.C.L., M.A.H. and M.W. wrote the paper.

Methods

Protein Expression and Purification of Human TRPV3.

An expression screen of 32 homologs of TRPV3 identified the human TRPV3 as the most suitable candidate for structural studies. To further stabilize hTRPV3, we searched a random

mutant library of mouse TRPV3⁴ for clones that exhibited either a large 2-APB response or a high baseline in a Ca²⁺-dependent fluorescence assay. We aimed to find mutants with higher expression levels due to increased stability. 50 clones were sequenced, and we introduced 28 point mutations into their corresponding sites in the hTRPV3. We expressed, purified, and tested the biochemical behaviour of these point mutants using size-exclusion chromatography, and found that the T96A mutant showed an improvement in the monodispersity of the full length human TRPV3 channel. The T96A mutation had a high rate of occurrence in tandem with other mutations, but did not appear on its own. Because in our patch clamp recording T96A does not affect the 2-APB response in hTRPV3, we reasoned that the enhanced calcium signals for the clones containing the T96A mutation was either due to the additional mutation present or the increase in the number of channels due to its enhanced stability by the T96A mutation.

A full-length human TRPV3 construct, containing mutation T96A was cloned into a pFastBac vector in frame with a FLAG affinity tag, and baculovirus was produced according to manufacturers' protocol (Invitrogen, Bac-to-Bac). For protein expression, Sf9 insect cells were infected with baculovirus at a density of 1.3 x 10⁶ cells ml⁻¹ and grown at 27° C for 72 hours in an orbital shaker. After 72 hours, cell pellets were collected, resuspended in buffer A (50 mM TRIS pH 8, 150 mM NaCl, 1 µg ml⁻¹ leupeptin, 1.5 µg ml⁻¹ pepstatin, 0.84 µg ml⁻¹ aprotinin, 0.3 mM PMSF, 14.3 mM β-mercaptoethanol, and DNaseI) and broken by sonication (3x30 pulses). 40 mM dodecyl β-maltoside (DDM, Anatrace) and 4 mM Cholesteryl Hemisuccinate Tris salt (CHS, Anatrace) were added to the lysate for extraction at 4° C for 1 hour. Unsolubilized material was removed by centrifugation (8,000 g, 30 minutes), and anti-FLAG resin was added to the supernatant for 1 hour at 4° C. For preparation of the apo sample, the resin was loaded onto a Biorad column and washed with 10 column volumes buffer B (50 mM TRIS pH8, 150 mM NaCl, 1 mM DDM, 0.1 mM CHS,

10 mM DTT) and the protein eluted in buffer C (50 mM TRIS pH 8, 150 mM NaCl, 1 mM DDM, 0.1 mM CHS, 0.1 mg ml⁻¹ 3:1:1 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphoethanolamine (POPE), 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phospho-(1'-*rac*-glycerol) (POPG), 10 mM DTT). For preparation of the sensitized TRPV3, the anti-FLAG resin was loaded onto a Biorad column and washed with 5 column volumes Buffer B (50 mM TRIS pH8, 150 mM NaCl, 1 mM DDM, 0.1 mM CHS, 10 mM DTT), followed by 5 column volumes Buffer B supplemented with 1 mM 2-APB. This was repeated 10 times, before the protein was eluted in 5 column volumes buffer C (50 mM TRIS pH 8, 150 mM NaCl, 1 mM DDM, 0.1 mM CHS, 0.1 mg ml⁻¹ 3:1:1 POPC:POPE:POPG, 10 mM DTT). For preparation of the TRPV3_{2-APB} sample, the same procedure was followed except buffer C was supplemented with 1 mM 2-APB. Following size exclusion chromatography, the protein peaks were collected, mixed with Poly (Maleic Anhydride-alt-1-Decene) substituted with 3-(Dimethylamino) Propylamine (PMAL-C8, Anatrace) (1:10 w/w ratio) and incubated overnight at 4° C with gentle agitation. Detergent was removed with Bio-Beads SM-2 (15 mg ml⁻¹) for 1 hour at 4° C. The reconstituted protein was further purified on a Superose 6 column in buffer D (50 mM Tris pH8, 150 mM NaCl). In preparation of the TRPV3_{2-APB} sample, Buffer D was supplemented with 1 mM 2-APB. Following size exclusion, the protein peak was collected and concentrated to 2-2.5 mg ml⁻¹.

Cryo-EM Sample Preparation.

Cryo-EM grid preparation was performed similarly for each TRPV3 specimen. Briefly, 3 µL of purified TRPV3 (0.35-0.5 mg/mL) was dispensed on a freshly plasma cleaned (Gatan Solarus) UltrAuFoil R1.2/1.3 300-mesh grid (Electron Microscopy Services) and manually blotted⁵⁰ using a custom-built manual plunger housed in a 4 °C cold room (>85% relative

humidity). Samples were blotted for 4-5 s with Whatman No. 1 filter paper immediately before plunge-freezing in liquid ethane cooled by liquid nitrogen.

Cryo-EM data acquisition and image processing.

All microscope alignments were performed on a cross-grating calibration grid according to previously described methodologies⁵¹ and all data were collected and pre-processed using the Leginon⁵² and Appion⁵³ software packages, respectively.

Apo TRPV3

Movies of apo TRPV3 were collected using a Thermo Fisher Titan Krios transmission electron microscope (TEM) operating at 300 keV with a Gatan K2 Summit direct electron detector (DED) operating in super-resolution mode (1.31 Å physical pixel size) at a nominal magnification of 22,500x. Movies were collected over a 12 second exposure with an exposure rate of ~9 e- pixel⁻¹ s⁻¹, resulting in a total exposure of ~63 e- Å⁻², using a defocus range of -0.5 μm to -2 μm. Motion correction was initially performed using Motioncorr⁵⁴ and the unweighted summed images (Fourier binned 2 × 2) were used for CTF estimation using CTFFIND4⁵⁵ (whole micrograph CTF estimation) to remove those micrographs with a confidence of fit below 90% were eliminated from further processing. Difference of Gaussian (DoG) picker⁵⁶ was used to automatically pick particles from the first ~100 micrographs and then subjected to reference-free 2D classification using multi-variant statistical analysis/multi-reference alignment (MSA/MRA)⁵⁷ (5.24 Å/pixel, 64 pixel box size). The best 2D classes that represented orthogonal views of TRPV3 were then used for template-based particle picking using FindEM⁵⁸. A final stack of 361,244 particle picks were then subjected to reference-free 2D classification using RELION⁵⁹ version 1.4 (5.24 Å/pixel, 64 pixel box

size) with the best 215,346 particles were subsequently 3D auto-refined using a 20-Å low-pass-filtered TRPV2 structure (EMDB-6455) as the initial model. Refined particles were then re-centered and re-extracted binned 2×2 (1.31 Å/pixel, 256 pixel box) and 3D auto-refined using a scaled version of the binned 8×8 map as the initial model. Particle movement and dose-weighting were then performed using the “particle polishing” feature as implemented within RELION. A smoothed plot of the per-frame B-factor and intercepts (SI Figure XX) were then used to calculate the frequency-dependent weighting. These “shiny” particles were then 3D auto-refined to yield a 3.95 Å resolution reconstruction (C1 symmetry). This reconstruction exhibited C4 symmetry. Subsequent no-alignment 3D classification using a mask generated against the full molecule low-pass filtered to 10 Å yielded a single good class that refined to 3.6 Å resolution (C4 symmetry). During the preparation of this manuscript the frame-alignment software MotionCor2⁶⁰ was released so the 282,136 particles contributing to the 3.6 Å resolution reconstruction were then re-centered and re-extracted from micrographs that had been aligned and dose-weighted using MotionCor2 without binning (0.655 Å/pixel) with per-particle CTF values as estimated using gCTF⁶¹. These particles were subjected to 3D classification where the best resolved class was subsequently 3D auto-refined to 3.5 Å resolution (C4 symmetry). These particles (120,424) were then subjected to a no-alignment 3D classification using a soft mask of the full molecule. The best resolving class (27,620 particles) was then 3D auto-refined (C4 symmetry) to a final resolution of 3.4 Å, as estimated by gold-standard FSC 0.143 criterion^{62,63}.

Sensitized TRPV3

Movies of sensitized TRPV3 were collected on a Talos Arctica (Thermo Fisher) TEM operating at 200 keV. Movies were collected using a K2 Summit DED in counting mode at a nominal magnification of 45,000x corresponding to a physical pixel size of 0.915 Å/pixel. A total of 2,982 movies (47 frames/movie) were collected using a 12 second exposure with an

exposure rate of ~4.7 e-/pixel/s, resulting in a total exposure of ~67 e-/Å² and a nominal defocus range from -0.8 μm to -1.4 μm. MotionCor2 was used to perform motion correction and dose-weighting. Unweighted summed images were used for CTF determination using CTFFIND4. FindEM was used for template-based particle picking using templates previously generated of apo TRPV3, yielding a stack of 559,206 picks that were binned 4 x 4 (3.66 Å/pixel, 112 pixel box size) and subjected to reference-free 2D classification using RELION 2.1⁶⁴. A total of 339,693 particles corresponding to the 2D classes displaying the strongest secondary-structural elements were input to 3D auto-refinement in RELION without symmetry imposed. The apo TRPV3 volume was low-pass filtered to 30 Å and used as an initial model. The refined coordinates were used for re-centering and re-extraction of 2 x 2 binned particles (1.83 Å/pixel, 224 pixel box size) and subjected to 3D classification (k=6) using a soft mask generated from the full molecule. A single class exhibiting C4 symmetry (44,553 particles) was 3D auto-refined with a soft mask and C4 symmetry applied to yield a ~3.7 Å reconstruction. These particles were re-centered and re-extracted unbinned (0.915 Å/pixel) and auto-refined to obtain a final resolution of ~3.24 Å (C4 symmetry).

TRPV3 with 2-APB

Movies of TRPV3 in the presence of 2-APB were collected on a Talos Arctica equipped with a K2 Summit DED operating in counting mode. Images were collected at a nominal magnification of 36,000x corresponding to a physical pixel size of 1.15 Å/pixel. A total of 1,908 movies (60 frames/movie) were collected using a 15 second exposure with an exposure rate of ~5.3 e-/pixel/s, resulting in a total exposure of ~60 e-/Å² and a nominal defocus range from -1.2 μm to -2 μm. All pre-processing (e.g. frame alignment, dose-weighting, CTF estimation, and particle picking) was performed as described above. A stack of 897,643 picks (binned 4 x 4, 4.8 Å/pixel, 72 pixel box size) were subjected to reference-free 2D classification in RELION. A subset of 589,656 particles corresponding to the best 2D

classes were subsequently 3D auto-refined with C4 symmetry imposed, using the apo TRPV3 volume low-pass filtered to 30 Å as an initial model. The particles were then subjected to 3D classification (k=6) without alignment, using a soft mask generated from the full molecule. A subset of 397,536 particles were selected and subsequently re-centered and re-extracted unbinned (1.15 Å/pixel, 288 pixel box size) and 3D auto-refined with C4 symmetry imposed to yield a ~3.6 Å reconstruction. An additional round of 3D classification (k=6) without alignment and without symmetry imposed revealed one state exhibiting C4 symmetry and two distinct states exhibiting C2 symmetry, which subsequently refined to ~3.5 Å (TRPV3_{2-APB 1}, C4 symmetry), ~4 Å (TRPV3_{2-APB 2}, C2 symmetry), and ~4 Å (TRPV3_{2-APB 3}, C2 symmetry), respectively.

Model Building and Analysis.

The apo TRPV3 model was built in the cryo-EM electron density map in Coot⁶⁵, using the structure of TRPV2 (PDB 5AN8) as a template for the transmembrane domains and the structure of the human TRPV3 ankyrin repeat domains⁴⁴ (PDB 4N5Q) as a template for the ARD. The structure was real-space refined in Coot, with ideal geometry constraints where appropriate. The model was iteratively refined using the phenix.real_space_refine command line⁶⁶ by global minimization and rigid body, while maintaining high weight on ideal geometry and secondary structure restraints. Molprobity⁶⁷ (<http://molprobity.biochem.duke.edu/>) was used to identify problematic regions, which were subsequently rebuilt in Coot. The refined apo TRPV3 model was used as a template for building the remaining 4 models. Radius along the permeation pathway was calculated using HOLE⁶⁸. All analysis and structure illustrations were performed using Pymol⁶⁹ and UCSF Chimera⁷⁰.

Normal Mode Analysis.

Normal mode analysis was performed on the apo TRPV3 structure using the backbone (C α) atoms using the program ProDy⁷¹ as recommended by the developers.

Electrophysiology.

HEK293T cells (62312975 – ATCC) were grown in DMEM supplemented with 10% FBS (Gibco), 1% penicillin/streptomycin (Gibco) and were sustained at 37°C in 5% CO₂. Cells between passage 10 – 30 grown in 40-mm wells were transiently transfected at ~50% confluence with plasmids encoding for either WT or T96A TRPV3 and green fluorescent protein (GFP) using FuGene6 (Promega). 24 hours post transfection, cells were reseeded onto 12-mm round glass coverslips (Fisher) and used 12 – 24 hours after for electrophysiological measurements.

Voltage-clamp recording were performed in the whole-cell patch configuration with electrodes pulled from borosilicated glass capillaries (Sutter Instruments) with a final resistance of 2.5 – 5 M Ω . Electrodes were filled with an intracellular solution containing (in mM) 150 CsCl, 1 MgCl₂, 10 HEPES, 5 EGTA, and adjusted to pH 7.2 (CsOH). Glass coverslips with adherent transfected cells were placed into an open bath chamber (RC-26G, Warner Instruments) and an extracellular solution containing (in mM) 140 NaCl, 5 KCl, 1 MgCl₂, 10 HEPES at pH 7.4 (NaOH) with and without (wash) 30 μ M 2-aminoethoxydiphenyl borate (2-APB) (Sigma) (prepared daily from DMSO stocks (1 M) stored at -80° C; final DMSO 0.03%) was focally applied with a pressurized perfusion system (BPS-8, ALA Scientific Instruments).

2-APB sensitization experiments were performed with a 30-s continuously repeating protocol (holding potential of +60 mV) in which the cell was first perfused with extracellular wash for 1-s, followed by a 15-s application of 2-APB extracellular solution, then preceded by 14-s of wash solution. The repeating recording protocol was then stopped when the 2-APB elicited responses no longer exhibited potentiation of the peak current amplitude. Current responses were low-pass filtered at 2 kHz (Axopatch 200B), digitally sampled at 5 – 10 kHz (Digidata 1440A), converted to digital files in Clampex10.7 (Molecular Devices) and stored on an external hard drive for offline analyses (Clampfit10.7, Molecular Devices; OriginPro 2016, OriginLab Corp.)

Data Analysis.

Sensitization parameters were evaluated by the stimulation dependent increase in the peak current amplitude measured at the end of each 2-APB exposure. Current amplitudes (I) from each stimulation were normalized to the maximum current (I_{max}) amplitude, and the fractional current (I/I_{max}) of each stimulation was plotted by stimulation number for each individual recording¹⁵. The stimulation time course of sensitization was fitted with a standard two-state Boltzmann equation:

$$\frac{I}{I_{max}} = \frac{1}{1 + e^{[(S-S_{50})/k]}}$$

with S the stimulation number, S_{50} the stimulation number corresponding to $I = I_{max}/2$, and the slope factor k , a fitted constant expressed in stimulation number representing the rate of change of sensitization. The fitted parameter values were obtained by fitting individual I/I_{max} vs. stimulation plots from biologically independent experiments and individual values were used to calculate the mean S_{50} and k for WT and T96A. The extent of sensitization was characterized by the relative increase in current obtained during the first (I_0) and maximum current (I_{max}) stimulation (I_{max}/I_0) and calculated as the mean from each biologically independent experiment.

Data availability.

The sequence of human TRPV3 can be found in the National Center for Biotechnology Information (accession code NM_145068.3). Coordinates have been deposited in the Protein Data Bank under accession codes XXXX, YYYY, ZZZZ, WWWW and QQQQ. Electron density maps have been deposited in the Electron Microscopy Data Bank under accession codes EMD- XXXX, EMD-YYYY, EMD-ZZZZ, EMD-WWWW and EMD-QQQQ.




Figure 1. Structural and functional characterization of the human TRPV3. a, 3D cryo-EM reconstruction of the apo human TRPV3 tetramer, colored by protomer. The C-terminal domain is shown in red. **b,** Overview of the structural elements within a single protomer of the TRPV3 channel: Ankyrin repeat domain (ARD) is shown in yellow; Coupling domain (CD), consisting of linker domain, pre-S1 and the C-terminal domain, is shown in red; Voltage sensing-like domain (VSLD), consisting of helices S1-S4, is shown in blues, the pore domain, consisting of helices S5-S6 and the pore helix, is colored in purple; the TRP domain is shown in green. **c-d,** Functional characterization of the TRPV3 wild type (**c**) and T96A mutant (**d**) channels. Representative whole-cell current traces recorded at +60 mV from TRPV3 wild-type and T96A channels evoked by repeated application of 30 μ M 2-APB for 15 s followed by complete washout (left) and corresponding time course of sensitization from the depicted recording (right). (TRPV3WT: $n = 7$ biologically independent experiments; TRPV3 T96A: $n = 6$ biologically independent experiments).




Figure 2. The conformational ensemble of human TRPV3. Overview of TRPV3 structures: apo (gold), sensitized (cyan), TRPV3_{2-APB} 1 (magenta), TRPV3_{2-APB} 1 (red), TRPV3_{2-APB} 3 (purple) (from left to right). Top panel shows the view from the membrane plane and the bottom panel represents the bottom-up view. Green sphere represents residue 145 and illustrates the positions of subunits relative to one another. Voltage sensing like domain (VSLD), pore and ankyrin repeat domain (ARD) are labelled.




Figure 3. Comparison of apo TRPV3 with thermoTRPV channels. **a**, Surface representation of the C-terminal domain (CTD) in TRPV3 compared to the CTDs in TRPV1, TRPV2 and TRPV4. The C-terminus of the CTD is resolved in TRPV3 and encircles the coupling domain (CD) β -sheet and forms an interface with the neighboring ARD (ARD^{+1}). **b**, Comparison of selectivity filters (SF) and helix bundle gates in TRPV3 (gold), TRPV1 (cyan), TRPV2 (blue), and TRPV4 (purple). SF residues are indicated by a shaded box and shown in stick representation. Residues representing the helix bundle gate are shown in stick representation. **c**, Overlay of the transmembrane domains (TM) of TRPV2 (marine) and TRPV3 (gold) of a single monomer. The TMs of TRPV2 are all α -helical, while the S4-S5 linker of TRPV3 contains a π -helical turn.




Figure 4. Comparison of apo and sensitized TRPV3. **a**, Comparison of HOLE profiles of the apo (gold) and sensitized (cyan) TRPV3 shows that the TRPV3 channel has different gates in the two different functional states: M677 in the apo closed state, and I674 in the sensitized closed state. The difference stems from a register shift induced by the formation of a π -helix in the sensitized state. **b**, Bottom-up view of the gate restrictions in the apo (gold, left) and sensitized (cyan, right) structures. **c**, The π -helix induces a $\sim 9^\circ$ bend in the bottom part of S6 in the sensitized state.




Figure 5. Formation of the π -helix in S6 changes the S4-S5 linker/pore domain interface.

a, The register of the α -helical S6 in the apo TRPV3 enables an interaction network between the Y575 in the S4-S5 linker and N671 and M672 in S6. Residue N671 is shown in sphere representation in top panel. **b**, Formation of a π -helix in the sensitized state, changes the register of the helix, so that N671 turns away from the S4-S5 linker and into the pore, where it interacts with the backbone of V666 residue in the π -helix. Residue N671 is shown in

sphere representation in top panel. **c**, Sequence alignment of TRP channel S6 helices. The conserved N residue (N671 in TRPV3) is marked in red.




Figure 6. Overview of pores in apo, sensitized and TRPV3 in the presence of 2-APB. a, Comparison of S6 helices of subunits A and C (top panel) and B and D (bottom panel) in apo (gold), sensitized (cyan), TRPV3_{2-APB 1-3} (magenta, red and slate). Residues representing the helix bundle gate are shown as sticks and spheres. **b,** Bottom-up view of the pores of apo (gold), sensitized (cyan), TRPV3_{2-APB 1-3} (magenta, red and slate). Residues representing the helix bundle gate are shown as sticks and spheres.




Figure 7. Reduced symmetry in the structures of TRPV3 obtained in the presence of 2-APB. **a**, Overlay of sensitized TRPV3 (cyan) and TRPV3_{2-APB} 2 (red). Subunits B and D of TRPV3_{2-APB} 2 undergo a $\sim 3^\circ$ rotation. **b**, Superposition of subunit B of sensitized TRPV3 (cyan) and TRPV3_{2-APB} 2 (red). The S4-S5 linker deviates from the alignment. **c**, Overlay of subunits A (light blue) and B (red) of TRPV3_{2-APB} 2. The S4-S5 linkers in the two subunits assume different conformations. **d**, Overlay of S5 helices of subunits A (light blue) and B (red) of TRPV3_{2-APB} 2. The two S4-S5 linkers have π -helices in different positions.

Table 1: Cryo-EM data collection, refinement and validation statistics.

	Apo hTRPV3	Sensitized hTRPV3	hTRPV3 ₂₋ APB 1	hTRPV3 ₂₋ APB 2	hTRPV3 ₂₋ APB 3
Data collection and processing					
Magnification	22,500x	45,000x		36,000x	
Voltage (kV)	300	200		200	
Electron exposure (e ⁻ /Å ²)	63	67		60	
Defocus range (μm)	-0.5 to -2	-0.8 to -1.4		-1.2 to -2	
Pixel size (Å)	1.31	0.915		1.15	
Detector	Super-Resolution	Counting		Counting	
Total extracted particles (no.)	361,244	559,206		897,643	
Refined particles (no.)	215,346	339,693		589,656	
Reconstruction					
Final particles (no.)	27,620	44,554	141,832	61,292	84,307
Symmetry imposed	C4	C4	C4	C2	C2
Nominal Resolution (Å)					
FSC 0.143 (unmasked/masked)	4.21/3.38	4.10/3.24	3.83/3.45	4.98/3.99	4.91/3.99
Map sharpening B factor (Å ²)	-73	-51	-145	-152	-144
Refinement					
<i>Model composition</i>					
Non-hydrogen atoms	17,032	17,784	18,336	17,892	16,956
Protein residues	2,404	2,428	2,452	2,452	2,436
Ligands	0	0	0	0	0
<i>Validation</i>					
MolProbity score	1.12	1.61	1.61	1.57	1.55
Clashscore	2.4	6	6	6	7
Poor rotamers (%)	0	0	0	0.1	0
<i>Ramachandran plot</i>					
Favored (%)	98	96	96	97	97
Allowed (%)	2	4	4	3	3
Disallowed (%)	0	0	0	0	0

References

- 1 Ramsey, I. S., Delling, M. & Clapham, D. E. An introduction to TRP channels. *Annual review of physiology* **68**, 619-647, doi:10.1146/annurev.physiol.68.040204.100431 (2006).
- 2 Bang, S., Yoo, S., Yang, T. J., Cho, H. & Hwang, S. W. 17(R)-resolvin D1 specifically inhibits transient receptor potential ion channel vanilloid 3 leading to peripheral antinociception. *British journal of pharmacology* **165**, 683-692, doi:10.1111/j.1476-5381.2011.01568.x (2012).
- 3 Bang, S., Yoo, S., Yang, T. J., Cho, H. & Hwang, S. W. Isopentenyl pyrophosphate is a novel antinociceptive substance that inhibits TRPV3 and TRPA1 ion channels. *Pain* **152**, 1156-1164, doi:10.1016/j.pain.2011.01.044 (2011).
- 4 Hu, H., Grandl, J., Bandell, M., Petrus, M. & Patapoutian, A. Two amino acid residues determine 2-APB sensitivity of the ion channels TRPV3 and TRPV4. *Proceedings of the National Academy of Sciences of the United States of America* **106**, 1626-1631, doi:10.1073/pnas.0812209106 (2009).
- 5 Sherkheli, M. A., Vogt-Eisele, A. K., Weber, K. & Hatt, H. Camphor modulates TRPV3 cation channels activity by interacting with critical pore-region cysteine residues. *Pakistan journal of pharmaceutical sciences* **26**, 431-438 (2013).
- 6 Klein, A. S., Tannert, A. & Schaefer, M. Cholesterol sensitises the transient receptor potential channel TRPV3 to lower temperatures and activator concentrations. *Cell calcium* **55**, 59-68, doi:10.1016/j.ceca.2013.12.001 (2014).
- 7 Xu, H., Delling, M., Jun, J. C. & Clapham, D. E. Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. *Nature neuroscience* **9**, 628-635, doi:10.1038/nn1692 (2006).
- 8 Cao, E., Cordero-Morales, J. F., Liu, B., Qin, F. & Julius, D. TRPV1 channels are intrinsically heat sensitive and negatively regulated by phosphoinositide lipids. *Neuron* **77**, 667-679, doi:10.1016/j.neuron.2012.12.016 (2013).
- 9 Velisetty, P. *et al.* A molecular determinant of phosphoinositide affinity in mammalian TRPV channels. *Scientific reports* **6**, 27652, doi:10.1038/srep27652 (2016).
- 10 Qin, N. *et al.* TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. *J Neurosci* **28**, 6231-6238, doi:10.1523/JNEUROSCI.0504-08.2008 (2008).
- 11 Nilius, B. & Owsianik, G. The transient receptor potential family of ion channels. *Genome biology* **12**, 218, doi:10.1186/gb-2011-12-3-218 (2011).
- 12 Clapham, D. E. & Miller, C. A thermodynamic framework for understanding temperature sensing by transient receptor potential (TRP) channels. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 19492-19497, doi:10.1073/pnas.1117485108 (2011).
- 13 Xu, H. *et al.* TRPV3 is a calcium-permeable temperature-sensitive cation channel. *Nature* **418**, 181-186, doi:10.1038/nature00882 (2002).
- 14 Chung, M. K., Lee, H., Mizuno, A., Suzuki, M. & Caterina, M. J. 2-aminoethoxydiphenyl borate activates and sensitizes the heat-gated ion channel TRPV3. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **24**, 5177-5182, doi:10.1523/JNEUROSCI.0934-04.2004 (2004).
- 15 Liu, B., Yao, J., Zhu, M. X. & Qin, F. Hysteresis of gating underlies sensitization of TRPV3 channels. *The Journal of general physiology* **138**, 509-520, doi:10.1085/jgp.201110689 (2011).
- 16 Peier, A. M. *et al.* A heat-sensitive TRP channel expressed in keratinocytes. *Science* **296**, 2046-2049, doi:10.1126/science.1073140 (2002).

17 Long, S. B., Campbell, E. B. & Mackinnon, R. Crystal structure of a mammalian voltage-dependent Shaker family K⁺ channel. *Science* **309**, 897-903, doi:10.1126/science.1116269 (2005).

18 Lai-Cheong, J. E. *et al.* Recurrent heterozygous missense mutation, p.Gly573Ser, in the TRPV3 gene in an Indian boy with sporadic Olmsted syndrome. *The British journal of dermatology* **167**, 440-442, doi:10.1111/j.1365-2133.2012.11115.x (2012).

19 Lin, Z. *et al.* Exome sequencing reveals mutations in TRPV3 as a cause of Olmsted syndrome. *American journal of human genetics* **90**, 558-564, doi:10.1016/j.ajhg.2012.02.006 (2012).

20 Kariminejad, A., Barzegar, M., Abdollahimajd, F., Pramanik, R. & McGrath, J. A. Olmsted syndrome in an Iranian boy with a new de novo mutation in TRPV3. *Clinical and experimental dermatology* **39**, 492-495, doi:10.1111/ced.12318 (2014).

21 Eytan, O. *et al.* Olmsted syndrome caused by a homozygous recessive mutation in TRPV3. *The Journal of investigative dermatology* **134**, 1752-1754, doi:10.1038/jid.2014.37 (2014).

22 Duchatelet, S. *et al.* A new TRPV3 missense mutation in a patient with Olmsted syndrome and erythromelalgia. *JAMA dermatology* **150**, 303-306, doi:10.1001/jamadermatol.2013.8709 (2014).

23 Yadav, M. & Goswami, C. TRPV3 mutants causing Olmsted Syndrome induce impaired cell adhesion and nonfunctional lysosomes. *Channels*, 0, doi:10.1080/19336950.2016.1249076 (2016).

24 Ni, C. *et al.* A novel mutation in TRPV3 gene causes atypical familial Olmsted syndrome. *Scientific reports* **6**, 21815, doi:10.1038/srep21815 (2016).

25 Agarwala, M. K., George, R., Pramanik, R. & McGrath, J. A. Olmsted syndrome in an Indian male with a new de novo mutation in TRPV3. *The British journal of dermatology* **174**, 209-211, doi:10.1111/bjd.13910 (2016).

26 Cheng, X. *et al.* TRP channel regulates EGFR signaling in hair morphogenesis and skin barrier formation. *Cell* **141**, 331-343, doi:10.1016/j.cell.2010.03.013 (2010).

27 Broad, L. M. *et al.* TRPV3 in Drug Development. *Pharmaceuticals* **9**, doi:10.3390/ph9030055 (2016).

28 Reilly, R. M. & Kym, P. R. Analgesic potential of TRPV3 antagonists. *Curr Top Med Chem* **11**, 2210-2215 (2011).

29 Cao, E., Liao, M., Cheng, Y. & Julius, D. TRPV1 structures in distinct conformations reveal activation mechanisms. *Nature* **504**, 113-118, doi:10.1038/nature12823 (2013).

30 Liao, M., Cao, E., Julius, D. & Cheng, Y. Structure of the TRPV1 ion channel determined by electron cryo-microscopy. *Nature* **504**, 107-112, doi:10.1038/nature12822 (2013).

31 Zubcevic, L. *et al.* Cryo-electron microscopy structure of the TRPV2 ion channel. *Nature structural & molecular biology* **23**, 180-186, doi:10.1038/nsmb.3159 (2016).

32 Huynh, K. W. *et al.* Structure of the full-length TRPV2 channel by cryo-EM. *Nature communications* **7**, 11130, doi:10.1038/ncomms11130 (2016).

33 Deng, Z. *et al.* Cryo-EM and X-ray structures of TRPV4 reveal insight into ion permeation and gating mechanisms. *Nature structural & molecular biology* **25**, 252-260, doi:10.1038/s41594-018-0037-5 (2018).

34 Jordt, S. E. & Julius, D. Molecular basis for species-specific sensitivity to "hot" chili peppers. *Cell* **108**, 421-430 (2002).

35 Gavva, N. R. *et al.* Molecular determinants of vanilloid sensitivity in TRPV1. *J Biol Chem* **279**, 20283-20295, doi:10.1074/jbc.M312577200 (2004).

36 Elokely, K. *et al.* Understanding TRPV1 activation by ligands: Insights from the binding modes of capsaicin and resiniferatoxin. *Proc Natl Acad Sci U S A* **113**, E137-145, doi:10.1073/pnas.1517288113 (2016).

37 Zhang, F. *et al.* Engineering vanilloid-sensitivity into the rat TRPV2 channel. *eLife* **5**, doi:10.7554/eLife.16409 (2016).

38 McGoldrick, L. L. *et al.* Opening of the human epithelial calcium channel TRPV6. *Nature* **553**, 233-237, doi:10.1038/nature25182 (2018).

39 Zubcevic, L. L., S.; Yang, H.; Lee, S.-Y. Conformational plasticity in the selectivity filter of the TRPV2 ion channel. *Nature structural & molecular biology*, doi:10.1038/s41594-018-0059-z (2018).

40 Singh, A. K., Saotome, K., McGoldrick, L. L. & Sobolevsky, A. I. Structural bases of TRP channel TRPV6 allosteric modulation by 2-APB. *Nature communications* **9**, 2465, doi:10.1038/s41467-018-04828-y (2018).

41 Autzen, H. E. *et al.* Structure of the human TRPM4 ion channel in a lipid nanodisc. *Science* **359**, 228-232, doi:10.1126/science.aar4510 (2018).

42 Duan, J. *et al.* Structure of full-length human TRPM4. *Proc Natl Acad Sci U S A* **115**, 2377-2382, doi:10.1073/pnas.1722038115 (2018).

43 Gao, Y., Cao, E., Julius, D. & Cheng, Y. TRPV1 structures in nanodiscs reveal mechanisms of ligand and lipid action. *Nature* **534**, 347-351, doi:10.1038/nature17964 (2016).

44 Shi, D. J., Ye, S., Cao, X., Zhang, R. & Wang, K. Crystal structure of the N-terminal ankyrin repeat domain of TRPV3 reveals unique conformation of finger 3 loop critical for channel function. *Protein & cell* **4**, 942-950, doi:10.1007/s13238-013-3091-0 (2013).

45 Lishko, P. V., Procko, E., Jin, X., Phelps, C. B. & Gaudet, R. The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. *Neuron* **54**, 905-918, doi:10.1016/j.neuron.2007.05.027 (2007).

46 Phelps, C. B., Wang, R. R., Choo, S. S. & Gaudet, R. Differential regulation of TRPV1, TRPV3, and TRPV4 sensitivity through a conserved binding site on the ankyrin repeat domain. *The Journal of biological chemistry* **285**, 731-740, doi:10.1074/jbc.M109.052548 (2010).

47 Lau, S. Y., Procko, E. & Gaudet, R. Distinct properties of Ca²⁺-calmodulin binding to N- and C-terminal regulatory regions of the TRPV1 channel. *The Journal of general physiology* **140**, 541-555, doi:10.1085/jgp.201210810 (2012).

48 Jiang, Y. *et al.* Crystal structure and mechanism of a calcium-gated potassium channel. *Nature* **417**, 515-522, doi:10.1038/417515a (2002).

49 Hite, R. K. & MacKinnon, R. Structural Titration of Slo2.2, a Na(+)-Dependent K(+) Channel. *Cell* **168**, 390-399 e311, doi:10.1016/j.cell.2016.12.030 (2017).

50 Dubochet, J. *et al.* Cryo-electron microscopy of vitrified specimens. *Q Rev Biophys* **21**, 129-228 (1988).

51 Herzik, M. A., Jr., Wu, M. & Lander, G. C. Achieving better-than-3-A resolution by single-particle cryo-EM at 200 keV. *Nat Methods* **14**, 1075-1078, doi:10.1038/nmeth.4461 (2017).

52 Suloway, C. *et al.* Automated molecular microscopy: the new Leginon system. *Journal of structural biology* **151**, 41-60, doi:10.1016/j.jsb.2005.03.010 (2005).

53 Lander, G. C. *et al.* Appion: an integrated, database-driven pipeline to facilitate EM image processing. *Journal of structural biology* **166**, 95-102 (2009).

54 Li, X. *et al.* Electron counting and beam-induced motion correction enable near-atomic-resolution single-particle cryo-EM. *Nat Methods* **10**, 584-590, doi:10.1038/nmeth.2472 (2013).

55 Rohou, A. & Grigorieff, N. CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *Journal of structural biology* **192**, 216-221, doi:10.1016/j.jsb.2015.08.008 (2015).

56 Voss, N. R., Yoshioka, C. K., Radermacher, M., Potter, C. S. & Carragher, B. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. *Journal of structural biology* **166**, 205-213 (2009).

57 Ogura, T., Iwasaki, K. & Sato, C. Topology representing network enables highly accurate classification of protein images taken by cryo electron-microscope without masking. *Journal of structural biology* **143**, 185-200 (2003).

58 Roseman, A. M. FindEM--a fast, efficient program for automatic selection of particles from electron micrographs. *Journal of structural biology* **145**, 91-99 (2004).

59 Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. *Journal of structural biology* **180**, 519-530, doi:10.1016/j.jsb.2012.09.006 (2012).

60 Zheng, S. Q. *et al.* MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* **14**, 331-332, doi:10.1038/nmeth.4193 (2017).

61 Zhang, K. Gctf: Real-time CTF determination and correction. *Journal of structural biology* **193**, 1-12, doi:10.1016/j.jsb.2015.11.003 (2016).

62 Scheres, S. H. & Chen, S. Prevention of overfitting in cryo-EM structure determination. *Nat Methods* **9**, 853-854, doi:10.1038/nmeth.2115 (2012).

63 Chen, S. *et al.* High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy. *Ultramicroscopy* **135**, 24-35, doi:10.1016/j.ultramic.2013.06.004 (2013).

64 Kimanius, D., Forsberg, B. O., Scheres, S. H. & Lindahl, E. Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. *eLife* **5**, doi:10.7554/eLife.18722 (2016).

65 Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. *Acta crystallographica. Section D, Biological crystallography* **60**, 2126-2132, doi:10.1107/S0907444904019158 (2004).

66 Adams, P. D. *et al.* PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* **66**, 213-221, doi:S0907444909052925 [pii]

10.1107/S0907444909052925 (2010).

67 Chen, V. B. *et al.* MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr D Biol Crystallogr* **66**, 12-21, doi:10.1107/S0907444909042073 (2010).

68 Smart, O. S., Neduvvelil, J. G., Wang, X., Wallace, B. A. & Sansom, M. S. HOLE: a program for the analysis of the pore dimensions of ion channel structural models. *Journal of molecular graphics* **14**, 354-360, 376 (1996).

69 The PyMOL Molecular Graphics System, Version 2.0

70 Pettersen, E. F. *et al.* UCSF Chimera--a visualization system for exploratory research and analysis. *Journal of computational chemistry* **25**, 1605-1612, doi:10.1002/jcc.20084 (2004).

71 Bakan, A., Meireles, L. M. & Bahar, I. ProDy: protein dynamics inferred from theory and experiments. *Bioinformatics* **27**, 1575-1577, doi:10.1093/bioinformatics/btr168 (2011).